The stock's fall snapped a two-day winning streak.

Truist analyst Srikripa Devarakonda lowered the firm’s price target on Biogen (BIIB) to $220 from $302 and keeps a Buy rating on the shares as ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Analysis of Biogen's stock performance in 2024, focusing on sales struggles, financial health, and valuation. Read more here.

Some new drugs have the potential to drive Biogen’s long-term growth. Let us discuss these factors in detail to understand how to play Biogen’s stock. Sales of MS drugs and Spinraza are ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Biogen (BIIB – Research Report) yesterday and set a price target of ...

A Suffolk Superior Court judge dismissed a biomanufacturing company’s lawsuit that claimed disruption caused by a Kendall ...

The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments.

Shares of Solid Biosciences (NASDAQ:SLDB) jumped 11% post-market after the company said the FDA had cleared an ...

Illustration shows a test tube in front of displayed Biogen logo (Reuters) - The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover ...

Analysts highlighted that Biogen’s Alzheimer's drug ... modest Leqembi (we're below consensus) and Skyclarys US (mostly penetrated), and real need for more pipeline and serious BD to get ...